Family PACT Update: DMPA-SQ Administration Guidelines

April 14, 2020

An article titled “DMPA-SQ Administration Guidelines Update” was posted to the NewsFlash area of the Medi-Cal website on April 9, 2020. The article stated that pursuant to the approval of a federal waiver allowing specific flexibilities related to the coronavirus disease 2019 (COVID-19) public health emergency, and to facilitate compliance with state and federal guidelines for sheltering in place and physical distancing, DHCS will temporarily allow for pharmacy dispensing of subcutaneous depot medroxyprogesterone acetate (DMPA-SQ) directly to the recipient for self-administration at home. This is in addition to current Medi-Cal policy that allows administration by a health care professional. This policy also applies to the Family Planning, Access, Care and Treatment (Family PACT) program.

Self-administration of DMPA-SQ would be at the option of the Family PACT client after individualized discussions and decision-making between the prescriber and the client. The prescribing provider is responsible for ensuring proper training of the client in administering the drug, potential side effects, and proper disposal of the pre-filled syringe. The full policy document is published on the COVID-19 webpage at Direct-to-Patient Dispensing of Subcutaneous Depot Medroxyprogesterone Acetate – COVID-19 Emergency. This temporary policy change is effective immediately and remains in effect until further notice.